Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5)

Cat. No.: HY-P992014: Data Sheet
FAQs
Technical Support

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) is an antibody targeting CXCR3, which specifically binds to an epitope within amino acid residues 23 to 44 of human CXCR3.

For research use only. We do not sell to patients.

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) Chemical Structure

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All CXCR Isoform Specific Products:

View All Isoforms

CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

Biological Activity
Purity & Documentation
References
Customer Review

Description

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) is an antibody targeting CXCR3, which specifically binds to an epitope within amino acid residues 23 to 44 of human CXCR3^[1].

Isotype

Mouse IgG2a kappa

Recommend Isotype Controls

Mouse IgG2a kappa, Isotype Control

Species Reactivity

Human/Mouse/Monkey

In Vitro

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) specifically binds to mouse, human, and marmoset CXCR3 expressed on transfected cells and primary immune cells^[1].
Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) binds to an epitope within amino acid residues 23 to 44 of human CXCR3^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) (2-5 mg/kg; i.v.; single/weekly; 7-21 days) increases pancreatic islet allograft survival in mice, with a single 5 mg/kg dose boosting mean graft survival time from 17 to 33 days, and weekly 2 mg/kg doses achieving 35 days MST with long-term survival in some animals^[1].
Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) (0.5-10 mg/kg; i.v.; single dose) dose-dependently depletes CXCR3-expressing CD4⁺, CD8⁺, and B cells in mice, with complete depletion at doses ≥ 2 mg/kg lasting for more than 3 weeks^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (streptozotocin-induced diabetic, pancreatic islet allograft recipients)^[1]
Dosage:	5 mg/kg (single pre-transplant dose); 2 mg/kg (weekly post-transplant doses); 2 mg/kg (weekly post-transplant + daily rapamycin for 7 days)
Administration:	i.v.; single dose (4-5 hours pre-transplant); i.v.; weekly (days 0,7,14,21 post-transplant); i.v.; weekly (days 0,7,14,21 post-transplant) + p.o.; daily (rapamycin, 7 days post-transplant)
Result:	Increased mean survival time (MST) of islet grafts from 17 to 33 days. Increased MST of islet grafts to 35 days, with 2 out of 7 mice showing graft survival >100 days. Resulted in 50% graft survival at 60 days.

Animal Model:	C57BL/6^[1]
Dosage:	0.5-10 mg/kg
Administration:	i.v.; single dose
Result:	Almost completely depleted CD4+/CXCR3+, CD8+/CXCR3+, and B220+/CXCR3+ cells within 4 days at doses of 2 mg/kg and higher; 0.5 mg/kg had no depletion effect. Maintained depletion of CXCR3+ cells for more than 3 weeks after a single 5 mg/kg dose. Reduced effector CD4+ T-cells (CD44high/CD62Llow) and memory CD4+ T-cells (CD44high/CD62Lhigh) from 27.1% to 13.5% relative to isotype control-treated mice after a single 5 mg/kg dose.

Gene ID

2833 [NCBI]

Accession

P49682-1

Target

CXCR3/GPR9/CD183

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

SMILES

[Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5)]

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Charles Reay Mackay, et al. Anticorps et leurs utilisations. WO2014186842A1. 2014.